癌症肽疫苗S-288310在晚期膀胱尿路上皮癌患者中的I/II期研究
这项I/II期研究纳入38例HLA-A*24:02阳性进展期膀胱尿路上皮癌患者,I期评估S-288310(1 mg或2 mg/肽)的安全性与耐受性,II期将32例随机分配至1 mg或2 mg组比较细胞毒性T淋巴细胞(CTL)诱导与安全性。S-288310安全且耐受良好,II期可评估免疫应答的27例中1 mg组与2 mg组CTL诱导率无差异(100% vs 80.0%),32例客观缓解率6.3%、疾病控制率56.3%,对两种肽均诱导CTL的患者总生存期长于无或仅一种肽诱导者。
要点
- S-288310在I期安全且耐受良好
- II期27例可评估者中1 mg组与2 mg组CTL诱导率无差异(100% vs 80.0%)
- 32例客观缓解率6.3%、疾病控制率56.3%
核心结论
- S-288310耐受良好并有效诱导肽特异性CTL,且CTL诱导与膀胱尿路上皮癌患者更长生存相关。
研究设计与样本
- I/II期研究,纳入38例HLA-A*24:02阳性进展期膀胱尿路上皮癌患者;I期3例1 mg、3例2 mg/肽皮下每周一次评估安全性与耐受性;II期32例随机分配至1 mg或2 mg组比较CTL诱导与安全性。
主要发现
- II期可评估免疫应答的27例中,1 mg组CTL诱导率100% vs 2 mg组80.0%,两组间无差异。
- II期接受S-288310的32例中,最常见药物相关不良事件为注射部位反应,见于29例(90.6%),无患者因该反应中止给药,频率与严重程度未见剂量关系。
- 32例客观缓解率为6.3%,疾病控制率为56.3%。
- 接受S-288310作为一线化疗后、2个方案后、3个或更多方案后接种的患者中位总生存期分别为14.4、9.1和3.7个月,一线治疗后2年生存率为32.2%。
- 对两种肽均诱导CTL的患者总生存期长于无或仅一种肽诱导CTL者。
关键数值与推荐
- I期1 mg或2 mg/肽皮下每周一次给药评估安全性与耐受性。
- II期1 mg组CTL诱导率100% vs 2 mg组80.0%,两组间无差异。
- 32例客观缓解率6.3%,疾病控制率56.3%。
- 一线化疗后、2个方案后、3个或更多方案后接种者中位总生存期分别为14.4、9.1和3.7个月,一线治疗后2年生存率32.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: S-288310, a cancer peptide vaccine composed of two HLA-A*24:02-restricted peptides derived from two oncoantigens, DEP domain-containing 1 (DEPDC1) and M-phase phosphoprotein 1 (MPHOSPH1), was investigated in urothelial carcinoma (UC) of the bladder. PATIENTS AND METHODS: Thirty eight HLA-A*24:02-positive patients with progressive UC were enrolled in this study. In the phase I part of the study, three patients each were treated with S-288310 at 1 mg or 2 mg/peptide subcutaneously once a week to evaluate safety and tolerability. In the phase II, 32 patients were randomized to receive either 1 mg or 2 mg to evaluate the difference in cytotoxic T lymphocytes (CTL) induction and safety. RESULTS: S-288310 was safe and well tolerated in the phase I. Of 27 patients evaluable for immune responses in the phase II, there was no difference in CTL induction rate between the 1 mg (100%) and 2 mg (80.0%) groups. Of 32 patients receiving S-288310 in the phase II, the most frequent drug-related AE was the injection site reaction that was observed in 29 patients (90.6%), but none of the patients discontinued administration due to these reactions and no dose relationship in the frequency and severity was observed. The objective response rate of the 32 patients was 6.3% and the disease control rate was 56.3%. The median overall survival (OS) rates for patients vaccinated with S-288310 after one regimen of chemotherapy, 2 regimens, or 3 or more were 14.4, 9.1 and 3.7 months, respectively, and 32.2% of patients post first-line treatment were alive at 2 years. OS of patients who showed CTL induction to both peptides was longer than that of those with CTL induction to no or one peptide. CONCLUSION: S-288310 was well-tolerated and effectively induced peptide-specific CTLs, which were correlated with longer survival for patients with UC of the bladder. TRIAL REGISTRATION ID: JapicCTI-090980.
引用
- Obara W, Eto M, Mimata H, et al. A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Ann Oncol. 2017. PMID: 27998971. doi:10.1093/annonc/mdw675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。